Monovisc Access in 2026: What Providers and Prescribers Need to Know

For orthopedic surgeons, rheumatologists, and sports medicine specialists, Monovisc remains a clinically preferred option for many patients with knee osteoarthritis — particularly those who benefit from a single-injection regimen using a high-dose, non-avian hyaluronic acid product. However, 2026 has brought continued insurance formulary complexity and administrative friction that impact patient access. This guide provides a clinical and operational summary of Monovisc's current landscape, with practical recommendations for your practice.

Clinical Overview: What Makes Monovisc Distinct

Monovisc is a cross-linked, high molecular weight sodium hyaluronate (1–2.9 million Daltons) delivered as a single 4 mL intra-articular injection (88 mg total HA, 22 mg/mL). It is manufactured by Anika Therapeutics using bacterial fermentation from Streptococcus equi — making it a non-avian product suitable for patients with poultry or avian protein allergies.

Monovisc delivers the maximum single-injection HA dose currently available in the U.S. market. Its proprietary cross-linking enhances viscoelasticity and residence time in the joint space, with clinical trial data demonstrating statistically significant improvements in WOMAC Pain Score and meaningful pain relief lasting up to 26 weeks post-injection.

FDA cleared Monovisc as a Class III medical device (PMA P090031) in 2014 for the treatment of pain caused by osteoarthritis of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics. It is approved for patients 21 years of age and older.

Supply Status in 2026: No Shortage, but Structural Access Barriers

There is no active FDA-declared shortage of Monovisc as of 2026. Anika Therapeutics has not reported manufacturing disruptions, and the wholesale supply chain through DePuy Synthes appears stable. Clinicians ordering through their existing specialty distributor accounts should be able to receive Monovisc within standard lead times (typically 2–5 business days).

The primary access challenge for patients is administrative rather than supply-driven: insurance formulary status and prior authorization requirements significantly limit which patients can practically access Monovisc at a covered cost. Understanding the current formulary landscape is essential for setting patient expectations and planning treatment timelines.

Insurance Formulary Landscape for Monovisc in 2026

Providers should be aware of the following formulary realities when prescribing Monovisc:

Medicare Part B (J7327): Monovisc is covered under Medicare Part B as a physician-administered medical device. The patient pays 20% coinsurance after meeting the Part B deductible. One injection per knee is typically approved every 6 months. Bilateral treatment is generally covered when both knees show documented OA. Medicare does not generally require prior authorization for Monovisc.

Aetna: Classifies Monovisc as non-preferred. Preferred single-injection alternatives are Durolane and Synvisc-One (no precertification required for preferred agents). Monovisc requires prior authorization with Aetna. Provide X-ray imaging, ICD-10 M17 diagnosis, and documentation of failed conservative treatment for ≥3 months.

Blue Cross Blue Shield: Coverage varies by state and plan. Monovisc is non-preferred on many BCBS plans; some state plans (including BCBS Illinois as of 2026) are reducing viscosupplement coverage. Federal Employee Program (FEP) members may retain Monovisc coverage. Always verify individual patient coverage before ordering.

UnitedHealthcare: Typically covers Monovisc with prior authorization; requires documentation of diagnosis, imaging, and failed conservative treatment. Some UHC plans may have specific preferred HA products. Verify at time of prescribing.

Prior Authorization: What Documentation Is Required

When submitting prior authorization requests for Monovisc with commercial insurers, prepare the following documentation package:

Diagnosis documentation: ICD-10 code M17 (or appropriate subcode) with clinical findings from physical examination

Radiographic imaging: X-ray within past 12 months showing joint space narrowing, osteophytes, or other degenerative changes consistent with knee OA

Conservative treatment failure: Documentation of ≥3–6 months of failed conservative treatment including physical therapy, NSAIDs/analgesics, and activity modification

Letter of medical necessity: For non-preferred status plans, include a letter explaining why Monovisc specifically is medically appropriate for this patient (e.g., avian allergy making Synvisc-One unsuitable; clinical preference for maximum-dose single injection)

J-code: Bill Monovisc using J-code J7327 for both Medicare and commercial submissions

Contraindications and Patient Selection Reminders

Monovisc is contraindicated in patients with:

Known hypersensitivity to hyaluronate preparations or gram-positive bacterial proteins

Systemic bleeding disorders (e.g., hemophilia) or use of anticoagulants that increase bleeding risk

Active infection in or around the knee joint or in surrounding skin

Patients 21 years of age or younger (safety and effectiveness not established)

Note: Do not use disinfectants containing quaternary ammonium salts for skin preparation, as they can cause precipitation of hyaluronate. Patients with severe intra-articular effusion should have effusion aspirated before injection using a separate syringe (use the same needle for aspiration and injection, but separate syringes).

Helping Patients Navigate Access Challenges

For patients who are insured but facing prior authorization delays or denials, early and thorough documentation preparation is the most powerful tool you have. For uninsured patients or those facing coverage gaps, medfinder for providers can help identify which practices near your patients have Monovisc in stock, and can help patients navigate access challenges efficiently.

See also our detailed provider guide on helping patients find Monovisc in stock for step-by-step workflows.